These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 15258401)

  • 21. Optimization and computational evaluation of a series of potential active site inhibitors of the V82F/I84V drug-resistant mutant of HIV-1 protease: an application of the relaxed complex method of structure-based drug design.
    Perryman AL; Lin JH; Andrew McCammon J
    Chem Biol Drug Des; 2006 May; 67(5):336-45. PubMed ID: 16784458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. On the role of the R configuration of the reaction-intermediate isostere in HIV-1 protease-inhibitor binding: X-ray structure at 2.0 A resolution.
    Dusková J; Dohnálek J; Skálová T; Petroková H; Vondrácková E; Hradílek M; Konvalinka J; Soucek M; Brynda J; Fábry M; Sedlácek J; Hasek J
    Acta Crystallogr D Biol Crystallogr; 2006 May; 62(Pt 5):489-97. PubMed ID: 16627941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography.
    Adachi M; Ohhara T; Kurihara K; Tamada T; Honjo E; Okazaki N; Arai S; Shoyama Y; Kimura K; Matsumura H; Sugiyama S; Adachi H; Takano K; Mori Y; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Kuroki R
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4641-6. PubMed ID: 19273847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of potent pyrrolidone-based HIV-1 protease inhibitors with enhanced drug-like properties.
    Kazmierski WM; Andrews W; Furfine E; Spaltenstein A; Wright L
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5689-92. PubMed ID: 15482949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disruption of the HIV-1 protease dimer with interface peptides: structural studies using NMR spectroscopy combined with [2-(13)C]-Trp selective labeling.
    Frutos S; Rodriguez-Mias RA; Madurga S; Collinet B; Reboud-Ravaux M; Ludevid D; Giralt E
    Biopolymers; 2007; 88(2):164-73. PubMed ID: 17236209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rational design and synthesis of a novel class of active site-targeted HIV protease inhibitors containing a hydroxymethylcarbonyl isostere. Use of phenylnorstatine or allophenylnorstatine as a transition-state mimic.
    Mimoto T; Imai J; Tanaka S; Hattori N; Takahashi O; Kisanuki S; Nagano Y; Shintani M; Hayashi H; Sakikawa H
    Chem Pharm Bull (Tokyo); 1991 Sep; 39(9):2465-7. PubMed ID: 1804562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Computational titration analysis of a multiprotic HIV-1 protease-ligand complex.
    Spyrakis F; Fornabaio M; Cozzini P; Mozzarelli A; Abraham DJ; Kellogg GE
    J Am Chem Soc; 2004 Sep; 126(38):11764-5. PubMed ID: 15382890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Crystal structure of chemically synthesized HIV-1 protease and a ketomethylene isostere inhibitor based on the p2/NC cleavage site.
    Torbeev VY; Mandal K; Terechko VA; Kent SB
    Bioorg Med Chem Lett; 2008 Aug; 18(16):4554-7. PubMed ID: 18657969
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conformational studies of irreversible HIV-1 protease inhibitors containing cis-epoxide as an amide isostere.
    Ro S; Baek SG; Lee B; Ok JH
    J Pept Res; 1999 Sep; 54(3):242-8. PubMed ID: 10517162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solution, solid phase and computational structures of apicidin and its backbone-reduced analogs.
    Kranz M; Murray PJ; Taylor S; Upton RJ; Clegg W; Elsegood MR
    J Pept Sci; 2006 Jun; 12(6):383-8. PubMed ID: 16342331
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins.
    Kageyama S; Anderson BD; Hoesterey BL; Hayashi H; Kiso Y; Flora KP; Mitsuya H
    Antimicrob Agents Chemother; 1994 May; 38(5):1107-11. PubMed ID: 8067746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The design and enzyme-bound crystal structure of indoline based peptidomimetic inhibitors of hepatitis C virus NS3 protease.
    Ontoria JM; Di Marco S; Conte I; Di Francesco ME; Gardelli C; Koch U; Matassa VG; Poma M; Steinkühler C; Volpari C; Harper S
    J Med Chem; 2004 Dec; 47(26):6443-6. PubMed ID: 15588076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of branched beta-carbon dehydro-residues on peptide conformations: syntheses, crystal structures and molecular conformations of two tetrapeptides: (a) N-(benzyloxycarbonyl)-DeltaVal-Leu-DeltaPhe-Leu-OCH3 and (b) N-(benzyloxycarbonyl)-DeltaIle-Ala-DeltaPhe-Ala-OCH3.
    Goel VK; Somvanshi RK; Dey S; Singh TP
    J Pept Res; 2005 Aug; 66(2):68-74. PubMed ID: 16000120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative modifications of kynostatin-272, a potent human immunodeficiency virus type 1 protease inhibitor: potential mechanism for altered activity in monocytes/macrophages.
    Davis DA; Read-Connole E; Pearson K; Fales HM; Newcomb FM; Moskovitz J; Yarchoan R
    Antimicrob Agents Chemother; 2002 Feb; 46(2):402-8. PubMed ID: 11796349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The methanol disolvate and the dihydrate of fexofenadine, an antihistamine drug.
    Tessler L; Goldberg I
    Acta Crystallogr C; 2005 Dec; 61(Pt 12):o707-10. PubMed ID: 16330854
    [TBL] [Abstract][Full Text] [Related]  

  • 37. X-ray structure of HIV-1 protease in situ product complex.
    Bihani S; Das A; Prashar V; Ferrer JL; Hosur MV
    Proteins; 2009 Feb; 74(3):594-602. PubMed ID: 18704947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational flexibility in the flap domains of ligand-free HIV protease.
    Heaslet H; Rosenfeld R; Giffin M; Lin YC; Tam K; Torbett BE; Elder JH; McRee DE; Stout CD
    Acta Crystallogr D Biol Crystallogr; 2007 Aug; 63(Pt 8):866-75. PubMed ID: 17642513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors possessing augmented P2' side chains.
    Smith AB; Charnley AK; Harada H; Beiger JJ; Cantin LD; Kenesky CS; Hirschmann R; Munshi S; Olsen DB; Stahlhut MW; Schleif WA; Kuo LC
    Bioorg Med Chem Lett; 2006 Feb; 16(4):859-63. PubMed ID: 16298527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
    Lu Y; Yang CY; Wang S
    J Am Chem Soc; 2006 Sep; 128(36):11830-9. PubMed ID: 16953623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.